Cohance Lifesciences Promoter Group Increases Stake to 6.36% via Inter-Se Transfer

The promoter group of Cohance Lifesciences Limited (formerly Suven Pharmaceuticals) has formalized an increase in their collective shareholding through an inter-se transfer. The total voting rights held by the group entities now stand at 6.36% of the total share capital post-acquisition. The transaction, dated February 23, 2026, involved the transfer of 77,00,000 equity shares, representing 2.01% of the voting capital, to consolidate holdings within the family trust structure.

Stake Consolidation in Cohance Lifesciences

An official disclosure has been filed detailing a change in shareholding for Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited). The transaction involved the acquisition of 77,00,000 shares, equating to 2.01% of the total voting capital, by entities within the promoter group. This acquisition was finalized on February 23, 2026.

Details of the Transaction

The acquisition was executed via Inter-se transfer through Block Deals. This maneuver served to consolidate ownership primarily under the Jasti Family Trust structure. The total number of shares acquired/sold during this specific event was 77,00,000 shares.

Shareholding Pre and Post-Transaction

Prior to this acquisition, the total holding of the acquirers (Jasti Property and Equity Holdings Private Limited and Persons Acting in Concert) stood at 2,43,26,009 shares, representing 6.36% of the total share capital. Following the transfer, the total holding remains at 2,43,26,009 shares, maintaining the group’s voting stake at 6.36%.

Holding Breakdown (Post-Acquisition):

  • Jasti Property and Equity Holdings Private Limited (Trustee): 96,16,009 shares (2.52%)
  • Jasub Property Holdings LLP (PAC): 1,47,00,000 shares (3.84%)

Capital Structure Context

The equity share capital of the Target Company (TC) remained constant throughout the transaction, recorded at 38,25,67,140 equity shares both before and after the sale. The total diluted share capital of the TC post-acquisition stands at 39,22,07,995 shares.

The disclosure was authorized by Venkateswarlu Jasti, acting on behalf of Jasti Property and Equity Holdings Private Limited, the sole Trustee of the Jasti Family Trust.

Source: BSE

Previous Article

L&T Finance Call Option Exercised on Subordinated Perpetual NCDs, Redemption Set for March 30, 2026

Next Article

Piramal Pharma Limited Disclosure of Key Managerial Personnel Contact Details